GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (OTCPK:ROSGQ) » Definitions » PS Ratio

Rosetta Genomics (Rosetta Genomics) PS Ratio : 0.00 (As of May. 24, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Rosetta Genomics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Rosetta Genomics's share price is $0.0001. Rosetta Genomics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2017 was $2.70. Hence, Rosetta Genomics's PS Ratio for today is 0.00.

The historical rank and industry rank for Rosetta Genomics's PS Ratio or its related term are showing as below:

ROSGQ's PS Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 3.065
* Ranked among companies with meaningful PS Ratio only.

Rosetta Genomics's Revenue per Sharefor the three months ended in Jun. 2017 was $0.34. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2017 was $2.70.

Back to Basics: PS Ratio


Rosetta Genomics PS Ratio Historical Data

The historical data trend for Rosetta Genomics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics PS Ratio Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 102.51 69.11 34.20 2.37 1.22

Rosetta Genomics Quarterly Data
Dec10 Mar11 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.76 2.28 1.87 1.22 0.86

Competitive Comparison of Rosetta Genomics's PS Ratio

For the Diagnostics & Research subindustry, Rosetta Genomics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rosetta Genomics's PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's PS Ratio falls into.



Rosetta Genomics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Rosetta Genomics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.0001/2.702
=0.00

Rosetta Genomics's Share Price of today is $0.0001.
Rosetta Genomics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.70.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Rosetta Genomics  (OTCPK:ROSGQ) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Rosetta Genomics PS Ratio Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rosetta Genomics (Rosetta Genomics) Business Description

Traded in Other Exchanges
N/A
Address
10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.
Executives
Sabby Management, Llc 10 percent owner 115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Sabby Healthcare Volatility Master Fund, Ltd. 10 percent owner C/O SABBY MANAGEMENT, LLC, 10 MOUNTAINVIEW ROAD, SUITE 205, UPPER SADDLE RIVER NJ 07458